For more than six years, MBVax Bioscience produced Coley Fluid and distributed it for compassionate use to countries where government regulators allowed its importation and use. The documented clinical responses of end-stage cancer patients treated according to the administration protocol show that Coley Fluid is a very effective cancer treatment with confirmed tumor regression in about 70% of cases and complete remission in about 20%.

These results must be confirmed in clinical trials, but regulators in Canada, Europe and the United States have denied permission because Coley Fluid production does not meet EU or FDA manufacturing standard for pharmaceuticals. Meeting these standards will require a new production facility. When financing is available, MBVax Bioscience plans to build a new production facility, obtain regulatory certification and commence clinical trials.

Coley Fluid stimulates an immune response that can be sufficiently powerful to induce the regression of cancer.

Dr. William Coley developed Coley Fluid in 1893. The first immune therapy for cancer became a mainstream treatment manufactured and distributed worldwide by several pharmaceutical companies. Coley Fluid was responsible for numerous well-documented complete remissions of advanced cancers that do not respond to modern therapies.

After Dr. Coley’s death in 1936, the use of Coley Fluid and the number of commercial suppliers declined. In the United Kingdom, the Lister Institute of Preventative Medicine ceased production in 1943, and in the United States, Parke Davis & Company ceased production in 1951. The German pharmaceutical company Südmedica ceased production in 1981 leaving no remaining commercial suppliers, and Coley Fluid was on the brink of becoming a footnote to medical history.

The decline of Coley Fluid coincided with the continued development and increased use of radiotherapy and chemotherapy. An obvious reason was the newer treatments were less labour intensive, but the fundamental reason for the decline of Coley Fluid was the lack of understanding of its mechanism of action. Without medical knowledge to guide clinical use, Coley Fluid results were unpredictable and inconsistent.

In 2002, the respected journal Science published Polly Matzinger’s groundbreaking paper “The Danger Model” that laid the essential groundwork to understanding the mechanism of action of Coley Fluid.

In 2003, two publications made the case for reviving Coley Fluid: “Dr William Coley and Tumour Regression” by Stephen Hoption Cann, Hans van Netten and Chris van Netten, and Spontaneous Regression Cancer and the Immune System by Donald H. MacAdam. In 2004, MacAdam and Cann decided to work together in the development of an optimal version of Coley Fluid with administration protocols based on a modern understanding of immunology. With support from a group of private investors, MBVax Bioscience was founded in 2005.

MBVax Bioscience developed an optimized version of Coley Fluid and an administration protocol based on a modern understanding of cancer immunology.

For more than six years, MBVax Bioscience administered a compassionate use program under which Coley Fluid was supplied to physicians who were legally able to import and administer Coley Fluid under the laws and regulations of their country.

The patients who received MBVax Coley Fluid therapy were almost exclusively end-stage, suffering from the many effects of previous treatments and with few remaining treatment options. Of cancer patients who received at least four weeks Coley Fluid therapy, physicians reported these results (including patients continuing to receive therapy):

About 90% of patients benefited from therapy including improvement in pain, appetite, depression, mobility, and/or regression of cancer.

  • About 70% of patients achieved confirmed regression of cancer.
  • About 20% of patients achieved complete remission (no detectable cancer).

Physicians reported confirmed regressions in advanced cancers including breast, brain, cervical, colon, esophageal, liver, lung, lymphoma, melanoma, multiple myeloma, ovarian, pancreas, prostate, rectal, sarcoma, stomach and tongue. Complete remissions (no remaining cancer) have been reported in lymphoma, melanoma, breast cancer, lung cancer, esophageal cancer and stomach cancer.